Clinical Trials Sponsored by Sobngwi Eugene

Total 1757 results

Sobngwi Eugene
University of Yaounde 1

Completed

Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension (SPIRY)

Diabetes Mellitus | Hypertension, Resistant to Conventional Therapy

Cameroon
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Yaounde Central Hospital
NGATI Denetria NYONGA, Dr; SOBNGWI Eugène, Pr; MBANYA Jean Claude, Pr

Completed

The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus (GINOFF1)

Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy

Cameroon
Center Eugene Marquis

Not yet recruiting

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer (CRANIUM)

HER2-positive Breast Cancer
Center Eugene Marquis

Recruiting

Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) (Lip-Re2)

Hepatocellular Carcinoma Non-resectable

France
Center Eugene Marquis

Suspended

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer (SIROCHO)

Resectable Intrahepatic Cholangiocarcinoma

France
Center Eugene Marquis

Completed

Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTIX)

Oropharynx Cancer

France
Center Eugene Marquis

Completed

Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors (GLIROPA)

Brain Neoplasms | Adult Brain Tumor

France
Center Eugene Marquis

Terminated

Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer (EnergiePancrea)

Metastatic Pancreatic Cancer

France
Center Eugene Marquis

Completed

Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients (AVA-CELL)

Glioma | Glioblastoma

France
Center Eugene Marquis

Recruiting

Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy (TEMPOS)

Prostate Cancer

France
Center Eugene Marquis

Recruiting

Prevention of Sequelae Pain After Breast Cancer Surgery by Self-massages and Self Stretching. Impact of Learning Workshops. (ESTAUVAL)

Breast Cancer | Surgery

France
Center Eugene Marquis

Completed

Evaluation of Music on the Level of Anxiety Felt During External Radiotherapy Sessions (MUSIC-RT)

Radiotherapy Side Effect

France
Center Eugene Marquis

Active, not recruiting

Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy (PACPAC-EPOC)

Solid Tumor, Adult | Chemotherapy Treatment | Advanced or Metastasis Stage

France
Center Eugene Marquis

Completed

Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma (MispheC)

Cholangiocarcinoma

France
Center Eugene Marquis

Terminated

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer (VesiCaP)

Overactive Bladder

France
Center Eugene Marquis

Withdrawn

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma. (INFLAGLI)

Glioma
Center Eugene Marquis

Completed

Adaptative Radiotherapy for Locally Advanced Cervical Cancer (ARCOL)

Uterine Cervical Cancer

France
Center Eugene Marquis

Completed

Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME) (ARTOME)

Oropharynx Cancer

France
Center Eugene Marquis

Completed

Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer (TEmPoRAL)

Locally Advanced Malignant Neoplasm | Malignant Neoplasm of Head and Neck

France
Center Eugene Marquis

Completed

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE)

Malignant Melanoma

France
Center Eugene Marquis

Completed

Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry

Adenoma, Liver Cell

France
Center Eugene Marquis

Terminated

Essential Oils on Anxiety of Patients Suffering From Cancer (RHECAP)

Neoplasm Metastasis

France
Center Eugene Marquis

Completed

Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium (ICY)

Hepatocellular Carcinoma

France
Cugene Inc.

Recruiting

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Autoimmune | SLE (Systemic Lupus)

United States
enGene, Inc.

Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Superficial Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

United States
Cugene Inc.

Active, not recruiting

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Systemic Lupus Erythematosus

United States
Celgene
Celgene Corporation

Completed

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Lymphoma | Cancer

United States, United Kingdom
Celgene Corporation

Completed

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Healthy Volunteers

United States
Celgene Corporation

Completed

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

United States
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Celgene Corporation

Completed

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Ireland, Spain, Australia, Austria, United Kingdom
Celgene Corporation

Completed

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Small Cell Lung Cancer

United States
Celgene Corporation

Withdrawn

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Celgene Corporation

Completed

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Neoplasms | Fatigue

United States
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Celgene
Celgene Corporation

Terminated

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors

United States
Celgene
Celgene Corporation

Completed

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States, Australia
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Celgene Corporation

Terminated

Prevention of Restenosis Following Revascularization

Vascular Disease, Peripheral

United States
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Celgene Corporation

Completed

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) (CRPS)

Complex Regional Pain Syndrome (RSD)

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene
Celgene Corporation

Completed

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell Lymphoma

United States, France, Germany, Poland, Russian Federation, United Kingdom
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States

3

Subscribe